HPS Pharmacies wish to give notice that Pfizer have discontinued the following parenteral antibiotic products:
|Cefazolin Sodium Hospira 1g||56374|
|Cefepime DBL 1g||161397|
|Cefepime DBL 2g||161412|
|Cefoxitin Sodium Hospira 1g||50310|
|Ceftazidime Hospira 1g||120543|
|Ceftazidime Hospira 2g||177030|
|Ceftriaxone Sodium Hospira 1g||167648|
|Ceftriaxone Sodium Hospira 2g||167651|
|Meropenem DBL 1g||161447|
|Meropenem DBL 500mg||161446|
|Piperacillin & Tazobactam DBL 4g/0.5||128752|
None of the above products are contracted by HPS, so there should be no immediate impact on sites.
The discontinuation of these items will decrease competition in the market and reduce the market’s ability to respond to medication shortages. HPS will continue to work with suppliers to ensure a structured and well-stocked supply chain.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 629 921 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates